FDA Approves World’s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults

Drug Development, Health Canada & FDA, Industry News, Study Results

The US Food and Drug Administration (FDA) has granted approval to GlaxoSmithKline (GSK) for Arexvy, the world’s first vaccine designed to protect older adults against respiratory syncytial virus (RSV). RSV is a common respiratory virus that can cause serious illness, particularly in adults over 65 years of age, and in infants and young children. It

GSK Announces Positive Data for its Respiratory Syncytial Virus Vaccine Candidate for Older Adults 

Drug Development, Industry News, Study Results

JoinAStudy.ca Investigators Dr. Peter Dzongowski, Dr. Michael Jones and Dr. Sean Peterson were all recently involved in GSK trial AReSVi 006, evaluating a vaccine candidate for Respiratory Syncytial Virus (RSV). Recruitment was highly successful for all three investigators, whose work has helped lead to the first RSV vaccine candidate to show statistically significant and clinically